Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs

Arthritis and Rheumatism

Volumn 52, Issue 11, 2005, Pages 3349-3359

  Brandt, Kenneth D ^a   Mazzuca, Steven A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CHONDROITIN SULFATE; DIACETYLRHEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; GLUCOSAMINE SULFATE; HYALURONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; RISEDRONIC ACID;

CHRONOPHARMACOLOGY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG CLEARANCE; DRUG WASHOUT; EVALUATION; HUMAN; JOINT RADIOGRAPHY; JOINT SPACE WIDTH; KNEE; MEASUREMENT; METHODOLOGY; OSTEOARTHRITIS; PAIN; PAIN ASSESSMENT; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; TREATMENT DURATION;

ANTIRHEUMATIC AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; JOINTS; MALE; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 27744455752     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21409     Document Type: Review

References (46)

1. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
2. Hubert HB, Bloch DA, Fries JF. Risk factors for physical disability in an aging cohort: the NHANES I follow-up survey. J Rheumatol 1993;30:480-8.
3. Yelin EH, Lubeck D, Holman H, Epstein W. The impact of rheumatoid arthritis and osteoarthritis: the activities of patients with rheumatoid arthritis and osteoarthritis compared to controls. J Rheumatol 1987;14:710-7.
4. Guccione AA, Felson DT, Anderson JJ. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health 1994;84:351-8.
5. Praemer A, Furner S, Rice DP. Musculoskeletal conditions in the United States. 2nd ed. Park Ridge (IL): American Academy of Orthopaedic Surgeons; 1992. p. 145-70.
6. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43:1905-15.
7. Pendleton A, Arden N, Dougados M, Doherty M. Bannwarth B, Bijlsma JW, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000;59:936-44.
8. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruycre O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6.
9. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double blind study. Arch Intern Med 2002;162:2113-23.
10. Michel BA, Stucki G, Frey D, de Vathaire F, Vignon E, Bruehlmann P, et al. Chondroitins 4 and 6 sulpfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005;52:779-86.
11. Uebelhart D, Malaise M, Marcolongo R, de Valthaire F, Piperno M, Mailleux E, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Ostearthritis Cartilage 2004;12:269-76.
12. Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 2005;52:2015-25.
13. Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial. Arthritis Res Ther 2005;7:R625-33.
14. Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M, et al. for the ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Arthritis Rheum 2001;44:2539-47.
15. Pham T, le Henanff A, Ravaud P, Dieppe P, Paolozzi L, Dougados M. Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NDR101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis 2004;63:1611-7.
16. Jubb RW, Piva S, Beinat L, Dacre J, Gishen P. A one-year, randomised placebo (saline) controlled trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiologic change in osteoarthritis of the knee. Int J Clin Pract 2003;57:467-74.
17. Lequesne M, Brandt K, Bellamy N, Moskowitz R, Menkes JC, Pelletier JP, et al. Guidelines for testing slow-acting and disease-modifying drugs in osteoarthritis. J Rheumatol 1994;21 Suppl 41:65-71.
18. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologies Evaluation and Research, Center for Devices and Radiological Health. Draft guidance for industry: clinical development programs for drugs, devices, and biological products intended for the treatment of osteoarthritis. URL: http://www.fda. gov/cder/guidance/2199dft.doc.
19. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimally clinically important improvement. Ann Rheum Dis 2005;64:29-33.
20. Strand V, Kelman A. Outcome measures in osteoarthritis: randomized controlled trials. Curr Rheumatol Rep 2004;6:20-30.
21. McAlindon T. Why are clinical trials of glucosamine no longer uniformly positive? Rheum Dis Clin North Am 2003;29:789-801.
22. Cibere J, Kopec JA, Thorne A, Singer J, Canvin J, Robinson DB, et al. Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum 2004;51:738-45.
23. Spector TD, Hart DJ, Doyle DV. Incidence and progression of osteoarthritis in women with unilateral knee disease in the general population: the effect of obesity. Ann Rheum Dis 1994;53:565-8.
24. Brandt KD, Mazzuca SA, Conrozier T, Dacre JE, Peterfy CG, Provvedini D, et al. Which is the best radiologic/radiographic protocol for a clinical trial of a structure-modifying drug in patients with knee osteoarthritis? Proceedings of January 17-18, 2002 Workshop in Toussus-le-Noble, France. J Rheumatol 2002;29:1308-20.
25. Mazzuca SA, Brandt KD, Katz BP, Lane KA, Bradley JD, Heck LW, et al. Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoarthritis drug. Arthritis Rheum 2004;51:933-40.
26. Lang JM. The use of a run-in to enhance compliance. Stat Med 1990;9:87-95.
27. Buckland-Wright JC, Macfarlane DG, Lynch JA, Jasani MK, Bradshaw CR. Joint space width measures cartilage thickness in osteoarthritis of the knee: high resolution plain film and double contrast macroradiographic investigation. Ann Rheum Dis 1995;54:263-8.
28. Adams JG, McAlindon T, Dimasi M, Carey J, Eustace S. Contribution of meniscal extrusion and cartilage loss to joint space narrowing in osteoarthritis. Clin Radiol 1999;54:502-6.
29. Hunter DJ, Tu X, LaValley M, Zhang YQ, Niu JB, Amin S, et al. The meniscus and cartilage loss [abstract]. Arthritis Rheum 2004;50 Suppl 9:S141.
30. Dougados M. Outcome measurements for clinical trials of disease modifying osteoarthritis drugs in patients with hip osteoarthritis. J Rheumatol 2004;31 Suppl 70:66-9.
31. Dougados M. Why choose hip osteoarthritis as a human model for evaluation of drugs in osteoarthritis? J Rheumatol 2005;32:1154-6.
32. Vignon E, Piperno M, Hellio le Graverand MP, Mazzuca SA, Brandt KD, Mathieu P, et al. Measurement of radiographic joint space width in the tibiofemoral compartment of the osteoarthritic knee: comparison of standing anteroposterior and Lyon Schuss views. Arthritis Rheum 2003;48:378-84.
33. Conrozier T, Favret H, Mathieu P, Piperno M, Provvedini D, Taccoen A, et al. Influence of the quality of tibial plateau alignment on the reproducibility of computer joint space measurement from Lyon schuss radiographic views of the knee in patients with knee osteoarthritis. Osteoarthritis Cartilage 2004;12:765-70.
34. Hellio le Graverand MP, Mazzuca SA, Lassere M, Guermazi A, Pickering E, Brandt KD, et al. Assessment of the radioanatomic positioning of the osteoarthritic knee in serial radiographs: comparison of three acquisition techniques. Osteoarthritis Cartilage. In press.
35. Buckland-Wright C. Protocols for precise radio-anatomical positioning of the tibiofemoral and patellofemoral compartments of the knee. Osteoarthritis Cartilage 1995;3 Suppl A:71-80.
36. Buckland-Wright JC, Macfarlane DG, Williams SA, Ward RJ. Accuracy and precision of joint space width measurements in standard and macroradiographs of osteoarthritic knees. Ann Rheum Dis 1995;54:872-80.
37. Messieh SS, Fowler PJ, Munro T. Anteroposterior radiographs of the osteoarthritic knee. J Bone Joint Surg Br 1990;72:639-40.
38. Mazzuca SA, Brandt KD, Buckwalter KA, Lane KA, Katz BP. Knee pain reduces joint space width in conventional standing anteroposterior radiographs of osteoarthritic knees. Arthritis Rheum 2002;46:1223-7.
39. Peterfy C, Li J, Ziam S, Duryea J, Lynch J, Miaux Y, et al. Comparison of fixed-flexion positioning with fluoroscopic semi-flexed positioning for quantifying radiographic joint-space width in the knee: test-retest reproducibility. Skeletal Radiol 2003;32:128-32.
40. Buckland-Wright JC, Wolfe F, Ward RJ, Flowers N, Hayne C. Substantial superiority of semiflexed (MTP) views in knee osteoarthritis: a comparative radiographic study, without fluoroscopy, of standing extended, semiflexed AP, and schuss views. J Rheumatol 1999;26:2664-74.
41. Bruyere O, Henrotin YE, Honore A, Rovati LC, Seidel L, Dardenne C, et al. Impact of the joint space width measurement method on the design of knee osteoarthritis studies. Aging Clin Exp Res 2003;15:136-41.
42. Pavelka K, Bruyere O, Rovati LC, Olejarova M, Giacovelli G, Reginster JY. Relief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials. Osteoarthritis Cartilage 2003;11:730-7.
43. Kellgren JH, Lawrence JS. Radiographic assessment of osteoarthritis. Ann Rheum Dis 1956;16:494-502.
44. Wolfe F, Lane NE. The longterm outcome of osteoarthritis: rates and predictors of joint space narrowing in symptomatic patients with knee osteoarthritis. J Rheumatol 2002;29:139-46.
45. Mazzuca SA, Brandt KD, Schauwecker DS, Meyer JM, Katz BP, Lane KA, et al. Severity of joint pain and Kellgren and Lawrence grade at baseline are better predictors of joint space narrowing than bone scintigraphy in patients with knee osteoarthritis. J Rheumatol 2005;32:1540-6.
46. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.